338 related articles for article (PubMed ID: 30386738)
1. Epigenetic Targeting of Glioblastoma.
Romani M; Pistillo MP; Banelli B
Front Oncol; 2018; 8():448. PubMed ID: 30386738
[TBL] [Abstract][Full Text] [Related]
2. Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O; Hegi ME
Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance.
Montella L; Cuomo M; Del Gaudio N; Buonaiuto M; Costabile D; Visconti R; Di Risi T; Vinciguerra R; Trio F; Ferraro S; Bove G; Facchini G; Altucci L; Chiariotti L; Della Monica R
Int J Cancer; 2023 Aug; 153(3):476-488. PubMed ID: 36479695
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
5. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract][Full Text] [Related]
6. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
Chan KM; Han J; Fang D; Gan H; Zhang Z
Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
[TBL] [Abstract][Full Text] [Related]
7. Targeting post-translational histone modifying enzymes in glioblastoma.
Kunadis E; Lakiotaki E; Korkolopoulou P; Piperi C
Pharmacol Ther; 2021 Apr; 220():107721. PubMed ID: 33144118
[TBL] [Abstract][Full Text] [Related]
8. Epigenomics in stress tolerance of plants under the climate change.
Kumar M; Rani K
Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.
Williams MJ; Singleton WG; Lowis SP; Malik K; Kurian KM
Front Oncol; 2017; 7():45. PubMed ID: 28401060
[TBL] [Abstract][Full Text] [Related]
10. Overview of DNA methylation in adult diffuse gliomas.
Aoki K; Natsume A
Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
12. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.
Cecener G; Tunca B; Egeli U; Bekar A; Tezcan G; Erturk E; Bayram N; Tolunay S
Cell Mol Neurobiol; 2012 Mar; 32(2):237-44. PubMed ID: 21928112
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Court F; Le Boiteux E; Fogli A; Müller-Barthélémy M; Vaurs-Barrière C; Chautard E; Pereira B; Biau J; Kemeny JL; Khalil T; Karayan-Tapon L; Verrelle P; Arnaud P
Genome Res; 2019 Oct; 29(10):1605-1621. PubMed ID: 31533980
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
15. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
Sahafnejad Z; Ramazi S; Allahverdi A
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
[TBL] [Abstract][Full Text] [Related]
16. Analytical and therapeutic profiles of DNA methylation alterations in cancer; an overview of changes in chromatin arrangement and alterations in histone surfaces.
Norollahi SE; Vahidi S; Shams S; Keymoradzdeh A; Soleymanpour A; Solymanmanesh N; Mirzajani E; Jamkhaneh VB; Samadani AA
Horm Mol Biol Clin Investig; 2023 Sep; 44(3):337-356. PubMed ID: 36799246
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Uddin MS; Mamun AA; Alghamdi BS; Tewari D; Jeandet P; Sarwar MS; Ashraf GM
Semin Cancer Biol; 2022 Aug; 83():100-120. PubMed ID: 33370605
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
[TBL] [Abstract][Full Text] [Related]
19. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
20. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.
Korshunov A; Capper D; Reuss D; Schrimpf D; Ryzhova M; Hovestadt V; Sturm D; Meyer J; Jones C; Zheludkova O; Kumirova E; Golanov A; Kool M; Schüller U; Mittelbronn M; Hasselblatt M; Schittenhelm J; Reifenberger G; Herold-Mende C; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2016 Jan; 131(1):137-46. PubMed ID: 26482474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
